IDM Pharma Updates Phase II Uvidem Results

IDM Pharma provided updated results from a Phase II Uvidem melanoma vaccine trial.

The single-arm, two-stage DC-MEL-202 trial evaluated the clinical and immunological activities and the incidence and severity of adverse events of a multivalent dendritic cell-based vaccine in patients with in-transit or low volume metastatic melanoma.

Of the 33 patients, 30 percent showed evidence of clinical benefit with one complete response, two partial responses and six stable disease with response duration ranging from 7.2 to 29.7 months. The survival rate at 12 months is 67 percent, and 18 patients are still alive, IDM said.

Uvidem was well tolerated with only one possibly related adverse event, age-related macular degeneration, reported.